Comparison of low- and high-dose recombinant activated factor VII for postcardiac surgical bleeding

Indian Journal of Critical Care Medicine

Volumn 20, Issue 9, 2016, Pages 497-503

  Habib, Aly ^a,b  

^a PRINCE SULTAN CARDIAC CENTER   (Saudi Arabia)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Bleeding; cardiac surgery; low dose; recombinant activated factor VIIa

Indexed keywords

FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BLOOD TRANSFUSION; CARDIAC SURGERY INTENSIVE CARE UNIT; CONTROLLED STUDY; CRYOPRECIPITATE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; HEART SURGERY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OFF LABEL DRUG USE; OPERATIVE BLOOD LOSS; PLASMA TRANSFUSION; POSTOPERATIVE HEMORRHAGE; REOPERATION; RETROSPECTIVE STUDY; THROMBOCYTE TRANSFUSION; THROMBOEMBOLISM;

EID: 84988353555     PISSN: 09725229     EISSN: 1998359X     Source Type: Journal    
DOI: 10.4103/0972-5229.190365     Document Type: Article

References (31)

1. Dyke C, Aronson S, Dietrich W, Hofmann A, Karkouti K, Levi M, et al. Universal definition of perioperative bleeding in adult cardiac surgery. J Thorac Cardiovasc Surg 2014;147:1458-63. e1.
2. Karkouti K, Wijeysundera DN, Yau TM, Beattie WS, Abdelnaem E, McCluskey SA, et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 2004;44:1453-62.
3. Karkouti K, Wijeysundera DN, Beattie WS, Callum JL, Cheng D, Dupuis JY, et al. Variability and predictability of large-volume red blood cell transfusion in cardiac surgery: A multicenter study. Transfusion 2007;47:2081-8.
4. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011;91:944-82.
5. Ferraris VA, Ferraris SP. Limiting excessive postoperative blood transfusion after cardiac procedures. A review. Tex Heart Inst J 1995;22:216-30.
6. Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 1996;111:1037-46.
7. Dacey LJ, Munoz JJ, Baribeau YR, Johnson ER, Lahey SJ, Leavitt BJ, et al. Re-exploration for hemorrhage following coronary artery bypass grafting: Incidence and risk factors. Northern New England cardiovascular disease study group. Arch Surg 1998;133:442-7.
8. Warren O, Mandal K, Hadjianastassiou V, Knowlton L, Panesar S, John K, et al. Recombinant activated factor VII in cardiac surgery: A systematic review. Ann Thorac Surg 2007;83:707-14.
9. Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: Randomized double-blind placebo-controlled pilot study. Br J Anaesth 2005;95:596-602.
10. Welsby IJ, Monroe DM, Lawson JH, Hoffmann M. Recombinant activated factor VII and the anaesthetist. Anaesthesia 2005;60:1203-12.
11. Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, et al. Systematic review: Benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011;154:529-40.
12. Al-Ruzzeh S, Navia JL. Letter by Al-Ruzzeh and Navia regarding article, "Safety and efficacy of recombinant activated factor VII: A randomized placebo-controlled trial in the setting of bleeding after cardiac surgery". Circulation 2010;121:e234.
13. Hauser CJ, Boffard K, Dutton R, Bernard GR, Croce MA, Holcomb JB, et al. Results of the CONTROL trial: Efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. J Trauma 2010;69:489-500.
14. Gill R, Herbertson M, Vuylsteke A, Olsen PS, von Heymann C, Mythen M, et al. Safety and efficacy of recombinant activated factor VII: A randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 2009;120:21-7.
15. Willis C, Bird R, Mullany D, Cameron P, Phillips L. Use of rFVIIa for critical bleeding in cardiac surgery: Dose variation and patient outcomes. Vox Sang 2010;98:531-7.
16. Andersen ND, Bhattacharya SD, Williams JB, Fosbol EL, Lockhart EL, Patel MB, et al. Intraoperative use of low-dose recombinant activated factor VII during thoracic aortic operations. Ann Thorac Surg 2012;93:1921-8.
17. White MC, Pryn SJ, Monk CR. Thrombogenic side-effects of recombinant factor VIIa after use in coronary artery bypass surgery. Anaesth Intensive Care 2006;34:664-7.
18. Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. The EuroSCORE II study group. Eur J Cardiothorac Surg 2012;41:734-45.
19. Brase J, Finger B, He J, Wirtz K, Stun L, McMillen R, et al. Analysis of outcomes using low-dose and early administration of recombinant activated factor VII in cardiac surgery. Ann Thorac Surg 2016;102:35-40.
20. Payani N, Foroughi M, Dabbagh A. The effect of intravenous administration of active recombinant factor VII on postoperative bleeding in cardiac valve reoperations; a randomized clinical trial. Anesth Pain Med 2015;5:e22846.
21. Safani M, Drachenberg MR, Ferro ET, Hill SE, Thomas GS, Bethencourt DM. Low-dose recombinant activated factor VII (rFVIIa) for excess hemorrhage after cardiac operation. Ann Thorac Surg 2015;99:1865-70.
22. Romagnoli S, Bevilacqua S, Gelsomino S, Pradella S, Ghilli L, Rostagno C, et al. Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. Anesth Analg 2006;102:1320-6.
23. Gelsomino S, Lorusso R, Romagnoli S, Bevilacqua S, De Cicco G, Billè G, et al. Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII [NovoSeven]: A propensity score analysis. Eur J Cardiothorac Surg 2008;33:64-71.
24. van de Garde EM, Bras LJ, Heijmen RH, Knibbe CA, van Dongen EP, Wiltink EH, et al. Low-dose recombinant factor VIIa in the management of uncontrolled postoperative hemorrhage in cardiac surgery patients. J Cardiothorac Vasc Anesth 2006;20:573-5.
25. Feih J, Rinka J, Ghadiali H, Kaiser M. High-versus low-dose recombinant activated factor VII use in cardiac surgery patients. Crit Care Med 2015;43(12 Suppl 1):152.
26. Alfirevic A, Duncan A, You J, Lober C, Soltesz E. Recombinant factor VII is associated with worse survival in complex cardiac surgical patients. Ann Thorac Surg 2014;98:618-24.
27. Chapman AJ, Blount AL, Davis AT, Hooker RL. Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery. Eur J Cardiothorac Surg 2011;40:1314-8.
28. Masud F, Bostan F, Chi E, Pass SE, Samir H, Stuebing K, et al. Recombinant factor VIIa treatment of severe bleeding in cardiac surgery patients: A retrospective analysis of dosing, efficacy, and safety outcomes. J Cardiothorac Vasc Anesth 2009;23:28-33.
29. Hacquard M, Durand M, Lecompte T, Boini S, Briançon S, Carteaux JP. Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: An observational study of practices in 23 French cardiac centers [2005-7]. Eur J Cardiothorac Surg 2011;40:1320-7.
30. Omar HR, Enten G, Karlnoski R, Ching YH, Mangar D, Camporesi EM. Recombinant activated factor VII significantly reduces transfusion requirements in cardiothoracic surgery. Drugs R D 2015;15:187-94.
31. Kouchoukos NT, Blackstone EH, Hanley FL, Kirklin JK. Kirklin/ Barrett-Boyes Cardiac surgery: Expert Consult. 4th ed. Philadelphia: Elsevier Saunders; 2013.